Rabies vaccine for human use and preparation method thereof

A technology of rabies vaccine and rabies virus, which is applied in the field of human rabies vaccine and its preparation, can solve the problems of inability to quickly treat diseases, low level of persistent immunity, and long immune response time, and achieve long duration of immunity, easy-to-obtain equipment, The effect of improving the immune response time

Active Publication Date: 2015-11-11
NINGBO RONGAN BIOLOGICAL PHARMA
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] In addition, the prior art also discloses the use of other types of compound adjuvants, but the immune response time of these rabies vaccines is relatively long, and the level of persistent immunity is also low, and neutralizing antibodies at an effective protective level cannot be produced in time after vaccination, resulting in the inability to quickly Curing disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Rabies vaccine for human use and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] The human rabies vaccine consists of the following components: 0.1 mg of zinc hydroxide, 10 μg of squalene, 10 μg of hyaluronic acid and 10 μg of Tween-80 are used as raw materials for each dose of the inactivated rabies virus vaccine.

[0027] Preparation method: Add zinc gluconate into sterile double-distilled water, fully stir and dissolve to obtain zinc gluconate solution. Sodium hydroxide was added into sterile double-distilled water, fully stirred and dissolved to obtain a sodium hydroxide solution. Under sterile conditions, the zinc gluconate solution and the sodium hydroxide solution were filtered and sterilized with a closed membrane filter respectively, and then used for later use. Under medium-speed stirring, slowly drop the sodium hydroxide solution into the zinc gluconate solution, and stir thoroughly to obtain the zinc hydroxide colloid, which is set aside;

[0028] Add squalene and hyaluronic acid into sterile double distilled water respectively, fully s...

Embodiment 2

[0031] The human rabies vaccine consists of the following components: 1 mg of zinc hydroxide, 100 μg of squalene, 100 μg of hyaluronic acid and 100 μg of Tween-80 are used as raw materials for each dose of the inactivated rabies virus vaccine.

[0032] Preparation method: same as Example 1.

Embodiment 3

[0034] The human rabies vaccine consists of the following components: 2 mg of zinc hydroxide, 300 μg of squalene, 300 μg of hyaluronic acid and 300 μg of Tween-80 are used as raw materials for each dose of the inactivated rabies virus vaccine.

[0035] Preparation method: same as Example 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a rabies vaccine for human use. The rabies vaccine is characterized by comprising a rabies virus inactivated vaccine material and a compound adjuvant, wherein the compound adjuvant is composed of zinc hydroxide colloid, squalene, hyaluronic acid and Tween-80; each dosage of the rabies virus inactivated vaccine material uses 0.1-10mg of zinc hydroxide colloid, 10-1000 mug of squalene, and 10-1000 mug of hyaluronic acid, and 10-1000 mug of Tween-80. With the adoption of the compound adjuvant, the immune response time is greatly prolonged, the neutralization is rapidly generated, the immuning capacity lasts for a long time, meanwhile, the preparation technology is simple, the needed equipment is easily available, the industrial production cost is reduced greatly, and the stability of the obtained rabies vaccine is also greatly improved.

Description

technical field [0001] The invention relates to a human rabies vaccine and a preparation method thereof, in particular to a human rabies vaccine containing a compound adjuvant and a preparation method thereof. Background technique [0002] Rabies is a natural epidemiological disease with a wide geographical distribution. It is prevalent in all continents of the world except Antarctica and Oceania. China is one of the countries with a high incidence of rabies, currently ranking second in the world. The main cause of human rabies is the increase in the number of dogs kept by the public, and the public's lack of awareness of the dangers of rabies, and the failure to take correct wound treatment and vaccination measures for those bitten by dogs are also important factors for the incidence of rabies. [0003] Anti-rabies immunization is one of the successful examples in the history of early immunological preventive medicine. As early as the 1880s, when Pasteur pioneered the use...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/39A61K39/205A61P31/14
Inventor 胡德东
Owner NINGBO RONGAN BIOLOGICAL PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap